Credit Suisse downgraded Amgen (NASDAQ: AMGN) from Outperform to Neutral and lowered the price target to $90.00. Credit Suisse commented, "The principal reason for our downgrade is that the 3 key elements of our July 2012 report entitled "Upgrading to Outperform = Agency cost + operational gearing + defensive macro call" have been realized, in our